Acute chest syndrome is the second most common cause of hospitalization and challenges infection 1 as the leading cause of sickle cell-related mortality 2 in children.
Still, management is largely based on the experience of individual practitioners, and there are no conclusive randomized controlled clinical trials to guide therapy. What follows is a review of treatment options and related issues to assist in management; it will likely be especially useful to those who do not regularly encounter children with this potentially life-threatening complication.
"What's in a name? That which we call a rose by any other name would smell as
sweet." William Shakespeare
Acute chest syndrome (ACS) is the term used to describe a new pulmonary infiltrate with respiratory findings in a person with sickle cell disease. 3 Etiology of these episodes is often multi-factorial and difficult to discern. While children may be more likely to have infectious etiologies for their chest syndrome and adults more likely sickle cell-related causes, 4, 5 infection and inflammation may well induce sickling, and embolism/infarction may lead to superimposed infection. This is perhaps best illustrated by the fact that two common causes of ACS, Chlamydia pneumoniae and Mycoplasma pneumoniae, are associated with a severe clinical course in individuals with sickle cell disease 6-9 rather than the "walking pneumonia" that typifies infection in others. It thus makes no sense to try to differentiate between "pneumonia" and ACS.
For personal use only. on September 24, 2017. by guest www.bloodjournal.org "Chance is a word that does not make sense. Nothing happens without a cause." Voltaire A multicenter National Acute Chest Syndrome Study (NACSS) 4 published in 2000 made aggressive attempts to identify etiology, including performance of bronchoalveolar lavage (BAL) on consenting study enrollees; 72% of the 671 enrolled in the study had a lavage or sputum sample available. Despite these efforts, the study only established potential causation in 38% overall and 70% of those with a complete assessment.
The most common identifiable cause of ACS was pulmonary fat embolism (PFE). 4 Originally described in trauma victims, PFE is a frequent complication of bone fracture and may progress to involve the lungs and central nervous system with multiorgan failure and death. 10, 11 The NACSS made the diagnosis utilizing BAL to identify fat-laden macrophages; less invasive means of making the diagnosis are not well established, and even the specificity of fat laden macrophages in BAL specimens has been questioned. 12 Vichinsky et.al, 13 in the first systematic, prospective search for PFE in sickle cell disease, found that 44 percent of patients with moderate to severe ACS had PFE as a probable etiology. These patients had longer, more severe hospital courses and greater decrease in hemoglobin concentration and platelet count than those without fat emboli. Fat from bone marrow, which is typically infarcted during acute pain episodes, 14 embolizes to the lungs and, in its most extreme form, pulmonary fat embolism syndrome may involve brain, kidneys and the liver 15 with substantial mortality. 16 It may be that, as with trauma, 11 fat emboli occur commonly with acute bone infarction, and clinical severity is a reflection of site and volume of marrow infarction. We generally reserve its use for older children with chest and back pain, supplementing it with morphine or hydromorphone as needed. We have not used nalbuphine hydrochloride, a mixed agonist antagonist opioid analgesic, which in a retrospective review of hospital records was associated with reduced incidence of nosocomial ACS.
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It appears to be equi-analgesic with morphine with fewer side effects; combination therapy with morphine was also found to be superior to either medication alone in a recent randomized trial of treatment for post-operative pain. 59 Optimizing pain control with decreased side effects, most critically ACS, should be a controlled trial priority; a prototype comparing two modes of administering patient-controlled analgesia was developed and piloted by the SCDRN (NCT00999245).
Pre-emptive therapy with transfusion, either preceding diagnosis (as attempted using sPLA2 as a marker) or at diagnosis (to avoid a prolonged course and/or respiratory failure) needs further study. In the NACSS (48 percent age 20 years or older) radiographic evidence of extensive lobar involvement, a platelet count of less than 200,000/cmm at diagnosis and a history of cardiac disease were independent predictors of respiratory failure. 4 In a small series of children, an arterial:alveolar oxygen gradient done at diagnosis on room air greater than 30 was predictive of a however, since ACS is often subtle at presentation and rapidly progressive, looking at pre-emptive therapy, especially utilizing transfusion, will be logistically difficult.
Children, at least those with homozygous sickle cell anemia, who recover from an episode of ACS should be offered therapy with hydroxyurea. In adults, hydroxyurea reduced the incidence of ACS by approximately 50% and the need for acute transfusion by 30% in the Multicenter Study of Hydroxyurea. 61 It appears safe and similarly effective when given to children. 62,63 Even infants, ages 9 -17 months at entry, treated on the BABY HUG trial had a 60% reduction in ACS over 2 years as compared to a placebo group, with predictable myelosuppression the only toxicity. 64 A single episode of ACS at any age should prompt discussion with the family regarding availability and potential use of hydroxyurea. While the long-term impact of preventive intervention is unknown, recurrent ACS has been associated with "sickle cell lung disease" and early mortality, 65 and repetitive episodes must be of concern.
Chronic transfusion therapy also may be offered as preventive therapy for children with recurrent ACS to reduce frequency of future episodes. At St. Jude patients transfused to maintain hemoglobin S less than 30% had a reduced risk of ACS incidence of ACS in children transfused for primary stroke prevention as compared to randomized controls. 67 We have rarely used transfusion specifically for recurrent ACS;
certainly it would be reserved now for the unusual child who had failed or could/would not take hydroxyurea.
"The rest is a mere matter of detail, to be settled with judgment, discretion, and caution." John Griffin Carlisle Hyponatremia is known to be common in children admitted for pain episodes 73 and likely occurs with ACS as well due to near ubiquitous sodium-losing nephropathy.
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Induction of hyponatremia was not proven to be beneficial and was difficult to safely maintain in treating acute pain episodes; 75 it has not been studied in ACS. We generally give extra sodium (five percent dextrose in water with 75 milli-equivalents of sodium chloride per liter) with intent to reduce the incidence/degree of hyponatremia and its potential complications.
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"Blood is thicker than water." Proverb Blood transfusion therapy is extremely useful in treating ACS. The earliest report of the benefit of transfusion was from Saudi Arabia several years ago. In a retrospective review, patients admitted with ACS and transfused within 24 hours had a 
NACSS. However, it is stated that patients who were given simple transfusion were no more likely to clinically worsen than those who received initial exchange; transfusion modality reflected preference of local investigators and was not necessarily based on clinical findings. 4 The only randomized trial of exchange versus simple transfusion, also organized by Dr. Vichinsky (a Brooklyn native and Downstate graduate), looked at preoperative preparation for elective surgery. 95 In 604 surgeries subjects were randomized to either simple (or, as the British say, "top-off") transfusion to raise the hemoglobin concentration to 9 -11 g/dL (mean post-transfusion hemoglobin 10.6 g/dL; hemoglobin S 59 percent), or exchange or repetitive simple transfusions to lower the hemoglobin S to less than 30 percent (mean hemoglobin 11 g/dL; mean hemoglobin S 31 percent).
There was no difference between the two transfusion groups in sickle cell-related or other surgical complications, except that allo-immunization and other complications of transfusion were more common in the exchange group. The incidence of ACS, the most common sickle cell related complication, was 10 percent in both groups.
The only circumstance in which we would use exchange transfusion as first-line therapy in ACS would be for a patient not sufficiently anemic to tolerate a simple transfusion; we do not administer transfusion volumes to sickle cell patients who are acutely ill that would raise their hemoglobin concentration above 11g/dL. If such patients require transfusion for the "dilute out sickle cells" effect, we generally use a partial exchange in which packed red blood cells are reconstituted using either saline or plasma. Blood is removed from the patient and replaced with equal volume in 20-50 ml aliquots; the reconstituted packed cells ideally should have a hemoglobin concentration of 10-11gm/dl. Alternatively, we have used donor bags for phlebotomy as described by The use of corticosteroids preventively in trauma-induced fat embolism syndrome is controversial. A recent meta-analysis 102 however suggested benefit in seven trials that were analyzed, with a 78 percent reduction in FES in subjects treated with 6 to 90 mg/kg over 48 hours. Patients treated with lower doses of methylprednisolone among this group appeared to fare best; early therapy using low dose corticosteroid therapy (1mg/kg/d by continuous infusion for 14 days with tapering to day 28) has similarly been proposed for adult respiratory distress syndrome. 103 We began using an asthma regimen of prednisone (2mg/kg/day for 5-7 days; maximum dose 60-80mg/day) thinking that this might provide the beneficial effects of dexamethasone without the readmission side effect; 94 prednisone actually reduces the relapse risk when used for treatment of status asthmaticus. 104 Of 53 episodes of ACS have, however, been impressed with the severity of diffuse pain in two of our patients who were re-admitted after prednisone treatment of ACS.
Investigators at Hartford describe their experience treating "severe" ACS utilizing both transfusion and dexamethasone. 106 While they felt the patient outcome was good and there was a low readmission rate, it is not clear whether or how much dexamethasone therapy may have added to the known beneficial effects of transfusion. Children who clinically worsen in spite of management as outlined should be referred for intensive care. We have been impressed with prompt and dramatic clinical improvement with administration of bi-level positive airway pressure (BiPAP). Again, although its benefits were reported years ago and I suspect it is widely used, it is often not mentioned in reviews of management of ACS and has not been prospectively studied; it should not be forgotten as an important management tool. 107, 108 While in the NACSS BAL was done safely in the majority of enrolled research subjects, complications did occur in 13% and were more common in those with dyspnea and higher respiratory rates. In my experience pulmonologists have been uncomfortable doing the procedure, either because the patient is too well to justify BAL or too sick to perform it safely. Since treatment of ACS should be inclusive, covering the likely infectious pathogens as well as fat-embolism or other sickle cell-related causes, BAL results would uncommonly impact decisions regarding therapy.
Patients with sickle cell disease tend to be somewhat thrombophilic with elevated fibrinogen and factor VIII and increased platelet number and aggregability. 109 While in situ thrombosis has been suggested as a cause of otherwise undiagnosed ACS in the should be advised that the steroid therapy might increase the risk of a pain episode shortly after resolution of ACS, but in our experience that is uncommon. Patients who have worsening pulmonary findings/de-saturation should then be transfused. A simple transfusion of 7-13ml/kg of packed red blood cells is the preferred initial treatment unless a patient's hemoglobin is greater than 9 gm/dl and a partial exchange using reconstituted packed cells is required. Assisted breathing using BiPAP may be helpful.
Patients who require mechanical ventilation should receive exchange transfusion or perhaps nitric oxide; hopefully there will be few such patients. Upon recovery, the efficacy of hydroxyurea in reducing the risk of future ACS episodes, along with its other potential risks and benefits, should be conveyed to patient and family.
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